| | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.190.284 |
| Chemical and physical data | |
| Formula | C13H13ClN2O |
| Molar mass | 248.71 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Selisistat (EX-527) is an experimental drug which is a potent and selective inhibitor of the SIRT1 protein. It was developed as a potential agent for the treatment of Huntington's disease, but also has potential applications in cancer treatment. [1] [2] [3] [4] [5]